ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023

        

ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023

• All resolutions voted with a large majority according to Board of Directors recommendations
• Company renamed Phaxiam Therapeutics, creating a world leader in phage therapy

         
Lyon (France), June 23, 2023 – ERYTECH Pharma (Euronext Paris & Nasdaq: ERYP) announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023

The adopted resolutions include:

• Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2022;
• Allocation of the financial year's results;
• Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;
• Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2022 to Gil BEYEN and Jean-Paul KRESS and of the compensation policy for executive corporate officers and board members;
• Renewal of the terms of office as Directors of Hilde WINDELS BV and Mrs. Martine George;
• Ratification of the appointment of Mr. Didier Hoch and Go Capital (Mrs. Leila Nicolas) as Directors;
• Appointment of Mr. Robert Sebbag and Mr. Eric Leire as Directors;
• Approval of the merger with Pherecydes and modification of the corporate name;
• Delegation of authority to the Board of Directors to carry out a reverse stock-split;
• Delegations of authority to the Board of Directors to issue shares or other marketable securities convertible into shares to be issued immediately or in the future by the Company, with or without preferential subscription rights for the shareholders;
• Authorization for the Board of Directors to grant free shares, share subscription and/or share purchase options and/or to issue share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma Group.